CSPC Pharma Receives $25 Million R&D Milestone Payment from AstraZeneca Under Strategic Collaboration and Licensing Deal

Stock News07-10

CSPC PHARMA (ASX: 01093) has announced that it has received a $25 million research and development milestone payment from AstraZeneca PLC (ASX: AZN).

This payment is part of a strategic collaboration and licensing agreement between the two companies, which aims to leverage CSPC's long-acting delivery technology platform and AI-driven peptide drug discovery platform to develop innovative long-acting peptide therapeutics.

The company's board of directors noted that this milestone payment, received on July 10, 2026, follows an initial upfront payment received on May 29, 2026, under the same agreement.

The achievement of this milestone signifies that the related research and development work under the agreement is progressing steadily according to plan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment